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Abstract
Dentists hold a key role in the context of ever-growing concerns regarding the 
management of Obstructive Sleep Apnea (OSA) in adults. Dentists’ contribution 
in this domain starts with the screening of patients with possible OSA. An earlier 
intervention for correcting a dento-maxillary anomaly or a parafunction will often 
serve as a preventive treatment with regard to possible OSA. Furthermore, dental 
medicine offers nowadays, apart from orthodontic and surgical treatment, a set 
of therapeutical methods, the most commonly used being the oral appliance and 
myofunctional therapies. Another important sphere of professional responsibility 
of the dentist involved in the treatment of OSA consists of periodical examinations 
focused on assessing clinical evolution, corrective interventions on oral appliances 
and interventions for preventing local complications. On the other hand, recent 
studies indicate the potential of different pharmacotherapy agents on OSA patho-
physiology, severity and treatment. These agents have shown promising results 
in improving the efficacy of other therapies dedicated to OSA, therefore, current 
topics in modern scientific research include the evaluation of standard, even higher 
doses of single agents or the combination of different agents on the evolution of 
OSA, as well as the assessment of the association of diverse pharmacotherapy agents 
with other OSA therapies.
Keywords: Obstructive Sleep Apnea, Dental Sleep Medicine, Oral Appliances, 
Myofunctional Therapy, Pharmacotherapy Agents
1. Introduction
Sleep disorders represent an increasingly common pathology, whose undesirable 
effects could profoundly affect patients’ every-day life. The sleep-related breathing 
disorders (SRBD) are placed by the American Academy of Sleep Medicine (AASM) 
among the six categories of sleep disorders in the International Classification of 
Sleep Disorders, Third Edition (ICSD-3) [1–3]: insomnia; sleep-related breathing 
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disorders; central disorders of hypersomnolence; circadian rhythm sleep–wake 
disorders; parasomnias; sleep-related movement disorders. Moreover, seep-related 
breathing disorders - that are characterized by abnormalities of respiration dur-
ing sleep - are classifies into four major categories: OSA (obstructive sleep apnea); 
CSA (central sleep apnea); sleep-related hypoventilation disorders; sleep-related 
hypoxemia disorder [4].
Obstructive Sleep Apnea (OSA) in adults represent a pathology included in the 
SRBD, which is associated with repetitive episodes of partial or complete collapse 
of the upper airway during sleep. As a result of these episodes, reduced (hypopnea) 
or absent (apnea) airflow lasting for at least 10 seconds is registered [3, 4]. In this 
specific context, the blood oxygen saturation is reduced and the brain is therefore 
alarmed, so “micro arousals” (“cortical arousal”) appear during sleeping. Apnea 
episodes can repeat hundreds of times a night, without the patient being aware 
of them. However, the sleep-quality becomes poor, physiological sleep-pattern is 
disturbed and the individuals are constantly tired during the day, their work perfor-
mance is affected and their quality of life decreases; moreover, individuals can even 
cause various work, road or domestic accidents due to excessive day-time sleepiness. 
OSA is a potentially life-threatening disease, its consequences including high blood 
pressure, diabetes, heart attack or stroke [3–5].
Obstructive sleep apnea (OSA) is traditionally quantified initially with testing 
during sleep by the apnea-hypopnea index (AHI), respiratory disturbance index 
(RDI) or respiratory event index (REI) [1, 4]. AHI results after analyzing a poly-
somnography (PSG) that is usually done in a sleep laboratory, and includes total 
episodes of apneas and total hypopneas per hour of sleep. RDI represents the sum 
of total apneas, total hypopneas and respiratory efforts related to arousals per hour 
of sleep. REI is a measure of respiratory events in a certain sleep unit of time, when 
using a home sleep apnea testing (HSAT); it is estimated that REI can underestimate 
the real index of respiratory events and OSA severity. However, the diagnosis of 
OSA is frequently based on the combination of clinical assessment and a diagnostic 
sleep study (an in-laboratory polysomnography/PSG or a home sleep study) [6].
OSA evidence-based therapeutic options includes: medical, surgical, behavioral 
strategies and adjuvant therapy/pharmacotherapy agents. Medical therapy is 
represented by PAP - positive airway pressure - therapy (CPAP/continuous positive 
airway pressure - the device deliver a steady pressure rate for both inhalation and 
exhalation); BPAP/bilevel positive airway pressure - the device deliver different 
pressure rates for inhalation and exhalation); APAP/automatic positive airway pres-
sure - automatically adjusts to meet each specific person’s night breathing needs) 
and oral appliances therapy (OAT), which aim is to reposition intraoral or cranio-
facial structures in order to increase the pharyngeal airway space, thus preventing 
pharyngeal collapse [4, 6].
Surgical options dedicated to OSA patients include: the reduction of soft tissues 
(i.e. adeno-tonsillectomy, uvulo-palatopharyngoplasty, tongue reduction), maxil-
lomandibular surgery, hyoid repositioning, the increment of nasal patency [7], 
hypoglossal nerve stimulation (HGNS).
On the other hand, behavioral strategies are represented by the following: 
weight loss - ideally up to a body mass index BMI <25 kg/m2; exercising; avoiding 
the consumption of tobacco and recreational substances; avoiding caffeine and 
alcohol before bed [1, 8]; positional therapy (non-supine position during sleep) 
[6, 9–12]. Different studies highlighted that weight loss is an important tool in 
OSA treatment, being effective in lowering OSA severity and reducing cardiovas-
cular risks [6, 13–15].
PAP treatment is considered first-line treatment for OSA, however, its adherence 
is often poor [5]. The necessity for novel treatment options to help those who cannot 
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adhere to positive airway pressure treatment is highly emerging. Regarding OAT 
therapy, which is enthusiastic received and applied by specialized trained dentists, 
several barriers were also identified, including the difficulty to accurately predict 
which patients will receive therapeutic benefit from this therapy and the possible 
side-effects related to oral appliances (OA). On the other hand, different classes of 
medication have been tested with regards to their effect on OSA severity. This paper 
will present dentists’ key role in the context of ever-growing concerns regarding the 
management of OSA in adults, in conjunction with relevant arguments that indicate 
the rising potential of different pharmacotherapy agents on OSA.
2. Dentist’s role in screening and treating OSAS
2.1 Identification of possible sleep disorders
In order to provide high-quality healthcare services to patients with OSAS, 
medical practitioners - including dentists - should adhere to the latest standards of 
care and should be able to participate effectively and efficiently in the management 
of these pathologies, according to evidence-based practices [1, 16]. Medical inter-
disciplinary collaboration represents a major element for diagnosis and treatment of 
patients with OSA. The expanding medical knowledge and the new advancements 
in scientific research on diverse OSA therapies place the dentist in a key-role posi-
tion in the context of managing OSA in adults. Along with other medical specialists 
(sleep medicine specialists, pneumologists, ENT - ear, nose, and throat specialists, 
neurologists, cardiologists, endocrinologists, bariatric surgeons, maxillofacial 
surgeons, psychiatrists, psychologists), the specialists in the domain of dental sleep 
medicine (DSM) can participate both in the identification of possible sleep disor-
ders and in the treatment of certain types of sleep pathologies (snoring, bruxism, 
mild or even moderate OSA), as well [17].
The specificity of the theoretical and practical content of dental medicine offers 
the practitioner of dental medicine the chance to contribute to solving medical-
dental problems for a large number of patients, whose age can range from youngest 
to oldest. The professional and social responsibility requires that the dentist pays 
special attention to specific morpho-functional aspects at the level of the dento-
maxillary apparatus (stomatognathic system) which, for certain patients, can 
suggest the presence of earlier or more advanced OSA manifestations.
Therefore, dentist’s role in the management of OSA starts with the screening 
of the patients visiting the dental office. The screening guidelines for detection of 
possible sleep disorders recommend that data can be collected even from anamnesis 
and clinical - general and local - direct observations. The “suspect patient” with 
possible OSA often has a specific profile, reporting: daytime sleepiness; difficulties 
in daily activities; chronic fatigue; attention, concentration and memory problems; 
behavioral disorders: irritability, anxiety, aggressiveness; episodes of wheezing, 
gasping, choking, snoring or bruxism during sleep (bruxism occurs in up to 95% 
of patients with OSA) [3, 4]; tooth tapping; night-sweating; leg or arm movements 
during sleep; frequent urination during night; dry mouth sensation in the morning; 
morning headaches and dizziness. These elements are frequently observed: obesity; 
large neck-size (>43 cm for men; >40 cm for women); hypertension; gastro-
esophageal reflux; age over 50; dysmenorrhea, amenorrhea, menopause; smoking; 
alcohol consumption [3, 4].
Along with these general aspects, dentist should notice and register local 
aspects that can be related to possible sleep disorders: large tonsils, voluminous 
posterior palatal soft tissues, hypotonic palatal or lingual musculature, tongue 
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size (macro-glosia), tongue indentation, maxillary compression, maxillary micro-
gnatism, micro-gnathism, mandibular retrognatism, deep palate, dental malposi-
tion, partial edentulous areas, tooth wear, narrow superior air-ways, oral breathing, 
deviated nasal septum, nose shape (narrowing) and obstructions [3, 4].
Nevertheless, patients with possible OSA will receive a thorough, complete 
oral examination of soft and hard tissues, and a direct examination of the tem-
poromandibular joint (TMJ) [18]. Intraoral and extraoral photographs, full dental 
arch impressions for obtaining dental study casts, intraoral scanning for obtaining 
digital models, conventional radiological exams and additional CBCT (Cone-beam 
computed tomography) exams are recommended.
Application of specific questionnaires represents another important “tool” in the 
screening of patients with possible OSA in the dental practice; the most used ques-
tionnaires are EPWORTH and STOPBANG questionnaires [17]. Ideally, dentists 
should apply the questionnaires for all patients that are susceptible of OSAS. Based 
on data collected from anamnesis, clinical and para-clinical investigations, and on 
questionnaires’ results, the dentists should refer the patients with possible OSA to 
the sleep medicine specialist.
2.2 Diagnosis and treatments of OSA: an interdisciplinary collaboration
In order to evaluate the sleep disorders, the sleep medicine specialists will per-
form specific clinical examinations and para-clinical tests on patients with possible 
sleep apnea, that were referred by the dentists (i.e. polysomnography – an overnight 
test that includes the monitoring of the patient’s airflow through the nose and 
mouth; blood oxygen level/pulse-oximetry; blood pressure; electrocardiographic 
activity/ECG; brain wave pattern/electroencephalogram/EEG; eye movement/
Electrooculography/EOG; movement of respiratory muscle and limbs). Additionally, 
interdisciplinary collaboration between sleep medicine specialists and pneumolo-
gists, cardiologists, E.N.T. -  ear, nose, and throat - specialists, neurologists, endo-
crinologists or psychiatrists is very useful for obtaining relevant data regarding 
the patient’s general health status. The sleep medicine specialists will establish the 
diagnosis and severity of OSA based on previously collected data [3, 4, 16], mostly 
determined by the combination of clinical assessment and a diagnostic sleep study 
(an in-laboratory polysomnography/PSG or a home sleep study) [6].
OSA are classified as central, obstructive and combined, depending on their 
specific ethio-pathogenic mechanism. As previously stated, apnea-hypopnea index 
(AHI) is a very important element in establishing the severity of OSAS; it represents 
the number of times in an hour when a sleeping person either stops breathing com-
pletely or inhales limited air-flow. Each episode must last at least 10 sec. AHI is a 
major indicator for obstructive sleep apnea, as follows: AHI of 30 or more events in 
an hour indicates severe sleep apnea; AHI = 15–30 events suggests moderate apnea; 
AHI = 5–15 events indicates mild apnea [3, 4].
The sleep medicine specialists are responsible for establishing the proper 
therapy for OSA patients. The therapeutic conventional options for OSA in adults 
are: medical, behavioral, surgical and adjuvant - pharmacotherapy agents.
CPAP (Continuous Positive Airway Pressure) Therapy - introduced by Sullivan in 
1981 - is considered the main treatment for OSA (severe, moderate and mild forms). 
The evaluation of the evolution of OSA under this specific therapy is assessed 
according to: reduction of daytime sleepiness, specific evaluation of OSA, patient 
and family satisfaction, adherence to therapy, achieving an optimal amount of sleep 
per day, practicing proper sleep hygiene, weight reduction, evaluation of factors 
that may aggravate the condition, titration (polysomnography/PSG) [3, 4]. CPAP 
therapy (Continuous Positive Airway Pressure Therapy) is frequently recommended 
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for severe sleep apnea. On the other hand, specific recommendations are usually 
accepted with regard to the oral appliance therapy [1, 16, 19, 20]. Oral appliance 
therapy should be used only when the patient cannot endure or refuses the CPAP 
therapy, as some specific problems related to the use of CPAP therapy can appear: 
dry mouth, eye watering, chest pressure, cold sensation, frequent awakenings, 
noise, mask-leak, skin irritations, claustrophobia [3, 4]. Adherence to CPAP therapy 
(defined as > 4 h average nightly use) is considered poor with only 46–83% being 
adherent, even for severe and moderate OSA [3, 4, 6, 21]. Additionally, the effec-
tiveness of oral appliances in these severe cases of OSA is estimated to be also poor. 
On the other hand, oral appliance therapy can be recommended as an additional 
treatment in the case of moderate apnea and can be the first-choice treatment in 
mild apnea cases. Moreover, the sleep medicine specialist who diagnoses the OSA 
refers the patients who could eventually benefit from OAT (oral appliance therapy) 
to the special trained dentist; following the complete specialized examination of the 
recommended patients, the dentist will decide the possibility of applying the oral 
appliance therapy (OAT).
2.3 Oral appliance therapy (OAT)
Oral appliance therapy (OAT), is considered - for more than 20 years - a mini-
mally invasive and effective treatment of OSAS. Oral appliances are represented by 
tongue retaining devices/TRD (which hold the tongue in a more anterior position) 
and mandibular advancement devices/MAD (mandibular advancement appliances 
or mandibular repositioning appliances/MRAs) [3, 4, 6, 22]. The reviewed scientific 
studies highlighted that the largest evidence base and guidelines exist for man-
dibular advancement devices [6]. These devices include a custom-made adjustable 
monobloc or double occlusal splint (corresponding to the upper and lower dental 
arches) that has the role to anteriorly reposition the mandible and the adjacent soft 
tissues (including the tongue) during sleep. This stabilized position of the mandible 
will enable a larger opening of the pharynx lumen, which mechanically keeps the 
upper airway open during sleep, by preventing the soft tissue of the throat and the 
tongue from collapsing into the airway [17, 20, 23]. It is strongly advisable that OSA 
treatment should never be initiated by a dentist without the patient’s assessment 
by a sleep medicine specialist. At this specific stage, interdisciplinary collaboration 
with orthodontists, specialists in prosthodontics, radiologists, specialists in geriatric 
dentistry, gerontologists, air-way prosthodontic specialists, TMD (temporo-
mandibular disorders)/Oro-facial pain specialists or maxillo-facial surgeons is 
recommended in order to carefully prepare the sequences of the treatment plan. 
The results obtain via general and local examination performed by the dentists are 
essential not only in identifying patients with possible OSAS, but in the confirma-
tion of the proper candidates for oral appliance therapy [18]. Moreover, the selection 
of the appropriate oral appliance for a specific clinical case is the responsibility of 
the dentists who are specialized in the treatment of sleep apnea [3, 4], and is influ-
enced by diverse elements, as follows: characteristics of cranio-facial structures; 
oral condition (number, location and health-status of remaining teeth; periodontal 
tissues status; soft tissue health); oral functionality; anticipated dental restorative 
needs; reported allergies and/or sensitivities; patients’ manual dexterity, visual acu-
ity and cognitive ability; patients’ comfort; financial considerations [1, 3, 4]. At the 
moment, more than 100 types of oral appliances are available on the medical market 
(i.e.: IST – Intraoral Snoring Appliance; Monoblock, Klearway; TAP-T Thornton 
Adjustable Positioner; Erkodent – Silensor; Somnodent; boil and bite – ready-made 
splints etc). A custom, titratable appliance is recommended versus a non-custom 
oral device [16, 19], as a successful oral appliance therapy (OAT) is considered to be 
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an integrated, customized treatment. The oral appliances are small-sized, portable, 
easy to tolerate and easy to clean.
The two occlusal splints of the oral appliance are connected by a special system 
that allows the stabilization of the mandible in a protrusive position. 75% of the 
maximum protrusion of the mandible, i.e. approximately 8-9 mm on average, is 
usually recommended to be determined and registered for the most oral appliances; 
this amount of protrusion is considered to be the maximum allowed for an oral 
appliance therapy dedicated to OSAS. The adjustment of mandibular advancement 
level (titration) is recommended to be included in the specific monitoring of OSA 
patient (part of the immediate check-ups and long-term follow-ups, as well).
Obtaining an oral appliance involves several successive steps: conventional 
impressions of the dental arches or intraoral scanning; obtaining the models of the 
dental arches (cast models, 3D printed models or digital ones); registration of the 
protrusive position of the mandible; project and fabrication of the oral appliance; 
oral appliance delivery: intra-oral placement, control and adjustments; use and 
homecare instructions delivery.
Regarding the registration of the protrusive position of the mandible for OAT, 
findings in medical literature suggest that a 25–75% protrusion is ranged as com-
fortable and yet therapeutic [24, 25]. On the other hand, maximizing the mandibu-
lar protrusion with oral appliances may be more important in severe cases of apnea. 
Different studies highlighted that the treatment results with oral appliances are 
better when the mandibular advancement is greater - however, possible associated 
local side effects should be observed and fixed [24, 26]. The protruded mandibular 
position can be determined and registered with special devices (i.e. “The George 
Gauge™ Kit”).
As stated before, patients undergoing oral appliance therapy should be informed 
and educated about the correct night-wear of the appliance, about its insertion, 
disinsertion and proper cleaning; morning exercises (using, for example, the 
Occlusion Trainer [18]), gymnastics and facial, head and neck massages are recom-
mended as well [1, 19].
Nevertheless, patients should be aware of the importance of weight control and 
sleep hygiene; a proper lifestyle, which involves a healthy diet, gymnastics, sports, 
avoiding caffeine, alcohol, tobacco or recreational substances [1, 3, 4, 8] can have 
a positive effect on the results of oral appliances therapy. Additionally, positional 
therapy is considered to be a beneficial adjunct to oral appliance therapy, in order to 
reduce AHI across total sleep time [6, 25, 27].
Oral myofunctional therapy (OMT) is also recommended to be associated with 
OA therapy [4]. Suzuki et al. showed that application of OMT was accompanied 
with a decrease of AHI by approximately 50% in a group of students with high 
Epworth Sleepiness Scale (ESS) [28]. Upper airway muscle training (oropharyngeal 
exercises, breathing, speech, swallowing, chewing exercises, movement of the 
tongue, nose, cheeks, and jaw) completed for 3 months (one hour per day) could 
decreased the AHI by 39% in patients with moderate OSA [29].
Immediate check-ups and also long-term follow-ups are needed after the inser-
tion of a mandibular advancement device (MAD). Appointments are made within 
the first days or, at least, within the first two weeks after the delivery of the oral 
appliance; patient comfort and the efficacy of the applied treatment should first be 
assessed by the dentists, along with small adjustments of the appliance that are also 
recommended, such as reduction of the pressure against the teeth or marginal fit 
adjustments. Titration/calibration of the oral appliance is a very delicate and impor-
tant aspect in oral appliance therapy. Continued gradual advancement of the man-
dible may bring further improvement of the symptoms related to OSA [1, 3, 4, 16]. 
On the other hand, sometimes reduction of the mandibular protrusion is necessary, 
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if adverse local effects are registered. The oral appliance therapy outcomes are 
evaluated by the sleep medicine specialists three months after the initiation of the 
OA treatment; a control polysomnography is recommended and the progress and 
benefits of the treatment should be registered.
Periodical examinations focused on assessing clinical evolution, corrective 
interventions on oral appliances, as well as the interventions for preventing the oro-
dental complications - that oral appliances can generate - represent another sphere of 
professional responsibility of the dental practitioner involved in the OSA treatment. 
Periodical dental and medical check-ups (every six months or at least once a year) are 
strongly recommended for long-term monitoring of patients with OSA. The manage-
ment of this patients in long term imply permanent communication between the den-
tists, the patient’s physician and other healthcare professionals that were involved in 
the treatment. The dentist should check and register: patient comfort; oral appliance 
efficacy; persistence of previously resolved symptoms related to OSA; the structural 
integrity and the occlusal stability of the oral appliance; wear, fractures; bacterial or 
fungal growth on the appliance [1, 4]. During this periodical dental examinations 
the appearance of possible side effects correlated to oral appliance therapy can be 
observed: muscle and joint soreness; soft tissue or gingival inflammation; excessive 
salivation or, on the contrary, dry mouth sensation; tooth mobility or fractures; teeth 
migrations and occlusion disturbances [3, 4, 30]. All side effects produced by the oral 
appliance therapy should be registered, documented and managed; it is important to 
determine the possible causes of these unpleasant side-effects and to try to reduce the 
damage. Balance between the actual need of oral appliance therapy and the severity 
of generated side effects should be evaluated in order to determine if oral appliance 
therapy should be discontinued and if the patient agree with another form of therapy 
recommended by the physician. Yet, Lavigne [4] consider that the adverse effects of 
oral appliances are generally considered to be negligible, mild or transient among 
most patients.
3. Pharmacotherapy agents and OSA pathophysiology
The use of medical-dental therapies, as stand-alone or in combination with 
other therapeutical alternatives for controlling OSA, represent a viable option in 
certain clinical cases, depending on the OSA clinical severity and/or the patient’s 
acceptance of the suggested solution. As pharmacotherapy agents have shown good 
results in improving the efficacy of other therapies dedicated to OSA, modern 
scientific research in the field of OSA focuses on the evaluation of diverse doses 
of single agents or the combination of different agents on the evolution of OSA. 
Another important aspect regards the association of diverse pharmacotherapy 
agents with other conventional OSA therapies.
Hypnotics represent a group of pharmacological agents that promote sleep 
and moderate sedation by depressing the central nervous system. Hypnotic use is 
relatively frequent for people diagnosed with OSA, as they usually experience cur-
rent insomnia [31]. Interest has grown steadily in the current scientific research to 
determine the specific effects of hypnotics on OSA severity, pathophysiology, their 
possible side-effects.
Benzodiazepines have sedative-hypnotic, myorelaxant, and anticonvulsive 
actions, in higher doses being commonly prescribed for insomnia [31]; early studies 
suggested that their use in patients with OSA has been controversial and can pos-
sibly worsen overnight hypoxemia in OSA [32, 33].
Hoijer et al. [32] reported in 1994 that nitrazepam did not adversely influence 
apnea intensity or severity in patients with mild to moderate sleep apnea; the 
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authors suggested that contraindicating benzodiazepine use in sleep apnea may be 
restricted to the patients with severe sleep apnea.
Late in 2011, a study conducted by Wang et al. [33], showed that mild–moderate 
OSA patients with higher awake central chemosensitivity have higher breathing 
impairment during sleep following the use of a hypnosedative - temazepam; in 
this context, the authors highlighted the clinical importance of phenotyping the 
individual OSA response to temazepam using ventilatory chemoreflexes during 
wakefulness.
A relatively recent study, conducted by Lin BM et al. [34] confirm that the use of 
benzodiazepine receptor agonists is not associated with increased odds of snor-
ing in middle-aged and elderly women. On the other hand, the administration of 
certain benzodiazepine sedatives in chronic pain patients on opioids induces mild 
respiratory depression, which is associated with reduced severity of OSA, probably 
increasing the arousal threshold [35]. However, some studies reported that benzo-
diazepines can produce poor motor coordination, dizziness or next-day drowsiness, 
and can alter the cognitive process and driving ability [31].
Certain pharmacological agents used to treat depression also have sedative 
effects, and thus are administered to improve night-sleep. As there is an increase 
need to augment OSA early detection, treatment options and strategies, emerging 
therapies such as non-benzodiazepine sedative hypnotics (NBSH) could be consid-
ered good alternative treatments, along with weight loss, positional therapy, oral 
appliances, or surgery [6]. Subjects with OSA usually demonstrate a low arousal 
threshold or propensity to wake easily in response to a disturbance. Sedatives were 
tried as a therapy for OSA, and different studies highlighted that sedative agents can 
increase arousal threshold [6, 36–39], for example, trazodone (100 mg, taken orally, 
90 min. before bedtime) - a non-myorelaxant sleep-promoting agent - increases the 
respiratory effort-related to arousal threshold [36] and eszopiclone (3 mg, imme-
diately prior to sleep) also increases the arousal threshold and lowers the AHI in 
obstructive sleep apnea patients [38].
Recently, Chen et al. [40] studied the effect of sedative antidepressants on the 
severity of OSA in stroke patients, as these medication is frequently prescribed 
for stroke patients due to their high prevalence of depression and insomnia. 
Patients were administered 100 mg of trazodone (Trazodone Tab, Taoyuan, 
Taiwan) just before polysomnography. The authors reported that trazodone may 
decrease OSA severity without increasing nocturnal hypoxia in OSA patients 
with comorbid ischemic stroke. On the other hand, it is acknowledged that 
trazodone - a tricyclic antidepressant - can cause severe toxicity at excessive 
doses [31].
Z-drugs represent a class of non-benzodiazepine agents (zolpidem, zopiclone, 
eszopiclone, zaleplon), with certain properties that make them more attractive: 
they have less adverse side effects, do not reduce deep sleep, and cause less residual 
daytime effects [31, 41].
The effects of zopiclone – a nonbenzodiazepine sedative – on the arousal thresh-
old and on genioglossus muscle activity were analyzed in a group of patients with 
predominantly severe OSA [42]; thus, the potential effects of zopiclone on obstruc-
tive sleep apnea (OSA) severity was studied. The results of this study showed that 
zopiclone (7.5 mg, taken orally, immediately prior to sleep) increased the arousal 
threshold without reducing genioglossus muscle activity; the authors noted that 
these aspects may be favorable for some patients with OSA.
However, despite of these promising results of different scientific studies, 
Eckert et al., early in 2014, [37], pointed out that no trial or evidence has demon-
strated a clear and significant improvement in severity of sleep disordered breath-
ing when sedative therapy is applied, even in patients with a low arousal threshold. 
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Moreover, Carter et al. [42] stated that zopiclone may worsen hypoxemia in some 
patients with OSA.
Yet, the effect of non-benzodiazepine sedative hypnotics (NBSH) on continu-
ous positive airway pressure (CPAP) adherence in patients with obstructive sleep 
apnea (OSA) was highlighted in a recent study [43]: the authors concluded that 
non-benzodiazepine sedative hypnotics administered in OSA patients may increase 
CPAP adherence (defined as CPAP use for >4 h/night, on >70% of nights); addi-
tionally, they noted that especially eszopiclone showed the most significant effect 
on CPAP adherence, however, the effect of zolpidem and zaleplon on CPAP adher-
ence requires further investigation.
Recently, orexin antagonists have been recommended primarily for people with 
insomnia [31, 44]. Certain roles of orexin neuropeptides (that are produced by 
neurons in the lateral hypothalamus) are represented by the regulation of sleep and 
arousal, as well of circadian rhythms; orexin neurons are activated during wakeful-
ness, but during sleep they are inhibited [45]. Consequently, dual orexin receptor 
antagonists (DORAs: almorexant, lemborexant, filorexant, suvorexant) may be 
considered an additional pharmaceutical option to treat insomnia in some patients 
[44]. For example, suvorexant showed a more balanced sleep architecture profile 
and greater potency than almorexant, yet, no clinically meaningful respiratory 
effects during sleep were observed in patients with mild or moderate OSA, receiv-
ing a single dose (40 mg) or multiple doses of suvoxerant [46]. As the influence 
of suvorexant in patients with severe OSA have not been profoundly studied, this 
medication must be used with caution and administered at lower doses in patients 
with OSA [44].
Along with the pharmacological agents listed and presented above, antihista-
mines (histamine antagonists) - that are often recommended in case of respiratory 
allergies - have also been used to treat mild insomnia. However, they are not associ-
ated with dependence, but tolerance can occur with their long-term use.
Additionally, Carter et al., in 2021 [31], concluded that common hypnotics 
can increase the respiratory arousal threshold by approximately 15–30% and have 
inconsistent effects on next-day alertness; however, in case of obese patients, severe 
OSA, higher respiratory arousal threshold, or at high doses, hypnotics can worsen 
overnight hypoxemia.
A stated before, different mechanisms can contribute to multifactorial OSA 
pathophysiology [5], including: increased collapsibility of the passive upper air-
way; impaired neuromuscular tone (relative hypotonia of upper airway dilator 
muscle/genioglossus muscle) and sympathetic neural activity; greater the loop 
gain; anatomic craniofacial features (increased anterior facial height, decreased 
pharyngeal airspace, inferiorly placed hyoid bone); high body mass index (obesity); 
rostral fluid shifts. This heterogenous pathogenesis can generate opportunities for 
therapies with diverse mechanisms of action: antihypertensive medication (acet-
azolamide; spironolactone), anti-inflammatory agents, antidiabetic medications, 
antidepressant medications or synthetic cannabinoids [5]. Moreover, Lavigne, in 
2009 [3], stated that “of all the metabolic syndrome components, OSA has been 
most strongly linked with hypertension”. Different scientific studies confirm this 
statement. Eskandari et al. [47], conducted a study in a group of men participants 
with moderate to severe OSA, which was divided in three sub-groups depending 
on the received treatment: acetazolamide therapy only; continuous positive airway 
pressure (CPAP) therapy only; acetazolamide plus CPAP therapy; the authors 
pointed out that a reduction in AHI was found in all three experimental groups, 
with the greatest reduction noted in the acetazolamide plus CPAP group. It was also 
demonstrated that spironolactone administered to patients with moderate–severe 
OSA and resistant hypertension produces a change in AHI from 36.6/hour at 
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baseline to 14.8/hour [48]. In the same line, Fiori et al. [49], showed that spirono-
lactone plus furosemide daily reduced AHI by 14.4%, after one week of treatment, 
versus sodium-restricted diet that reduced AHI by 22.3% and versus 0.8% reduc-
tion of AHI correspondent to the placebo monotherapy.
As regard of Sodium-glucose Cotransporter-2 inhibitors (SGLT-2 inhibitors), 
there are previous studies indicating that SGLT-2 inhibitors may reduce OSA 
severity. Furukawa et al. [50] found that dapagliflozin might improve moderate 
to severe sleep-disorders breathing in Japanese patients with obesity and type 2 
diabetes mellitus (mean AHI decreased from 25/hour to 19/hour). Tang et al. [51] 
considered that dapagliflozin could demonstrate therapeutic value for patients with 
T2DM (type-2 diabetes mellitus) combined with OSA; this study highlights that 
dapagliflozin can significantly reduce glucose, BMI, blood pressure and AHI and 
improve hypoxemia during sleep, therefore, indicates that dapagliflozin has poten-
tial as an effective treatment approach for OSA.
On the other hand, limited studies have been conducted in patients with 
OSA in order to demonstrate reduction in AHI with synthetic cannabinoids use. 
Yet, recently, Taranto-Montemurro L et al. [52] showed for the first time that 
the combination of a norepinephrine reuptake inhibitor (atomoxetine/80 mg at 
bedtime) and an antimuscarinic (oxybutynin/5 mg at bedtime) clearly reduces 
OSA Severity (>50%); the authors suggested these results may reorient future 
treatment of OSA.
4. Conclusions
It is well acknowledged the complexity of OSA, its heterogeneity in terms of risk 
factors and consequences, pathophysiological phenotypes, clinical presentation, and 
comorbidity [6, 53]. We understand more and more the importance of phenotyping 
patients with OSA (clinical, anatomical, genetic and polysomnographic pheno-
typing, biomarkers assessment, life style factors evaluation) and identifying the 
patients that can benefit from a pharmacotherapy that targets their major predispos-
ing factors [4, 6]. This aim implies advanced validation of the phenotyping tools and 
algorithms that should be used to identify the principal factors precipitating OSA in 
individual patients [53]. The interconnected risk factors for OSA needs to be con-
sidered in order to achieve precision medicine in OSA [4]. Pharmacotherapy agents 
may have an important role as monotherapy in the treatment of mild OSA, or could 
be used in association with other therapies in moderate-to-severe OSA, including 
oral appliances therapy (OAT), provided by dentists trained in dental sleep medicine 
(DSM). Additionally, as patient-centered care is the future, recognizing and under-
standing patient profound medical needs, preferences, their psychological status, 
expectations and beliefs [4] contribute in the successful implementation of OSA 
complex therapies.
Moreover, considering the interest shown in the field of TMD (temporo-man-
dibular disorders) and oro-facial pain for under and post-graduate students train-
ing, and given the important role of the dentist in the early detection, treatment 
and monitoring of patients with OSA and sleep bruxism, it is necessary that the 
aspects related to dental sleep medicine (DSM) should also be found in a multi- and 
inter-disciplinary organized form in university curricula (stand-alone disciplines, 
courses, practical training), this approach corresponding to the growing need for 
treatment of this pathology in the general population.
An important issue is the one related to the actual “dental/clinical complex 
symbiosis” in OSA therapy, that should lead to improved personal medical care. 
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The combined modern therapies for OSA (medical, surgical, behavioral strategies, 
pharmacotherapy agents) have to be adjusted continuously, in respect to recent 
scientific research, in order to deliver the best results for patients, emphasizing their 
quality of life in addition to medical care.
Current - Western allopathic medicine benefits from the accumulation of large 
fundamental biomedical knowledge, special equipment, modern materials and 
techniques.
Medical specializations and supra-specializations offer increased chances for 
therapeutic success, provided that the early diagnosis and therapeutic indication 
are as accurate as possible and the patient has proper, legitimate access to the health 
services provided by the medical staff.
The complexity of clinical cases varies between patients, and the clinical com-
plexity of a single clinical case can evolve towards simplification or, on the contrary, 
towards increased complexity. The greater the complexity of a clinical case is, the 
greater is the need for multidisciplinary collaboration, in order to increase the 
accuracy of medical decisions.
In our opinion, the previous considerations are also valid in the case of OSA, 
whose etiopathogenic and clinical complexity requires such an approach. To meet 
such a requirement - that focuses on the quality of life of the patient, with his unique 
bio-psycho-social-cultural profile, unlikely repeatable - health care systems, along 
with socio-economic, cultural or political systems must act in multiple directions.
First of all, the health systems should be provided with the necessary medical 
personnel, having various clinical specializations; nevertheless, medical personnel 
should have a balanced territorial distribution and it should be open to continuous 
training and inter-disciplinary collaboration.
Secondly, regarding the rapidly evolving topic represented by OSA, which obvi-
ously represents an interdisciplinary chapter of human pathology, it would be inter-
esting to organize university courses with interdisciplinary content, that are opened 
to all students in both medicine and dentistry. This approach can create a strong 
basis for future interdisciplinary clinical collaborations between post-graduates. 
Importantly, the medical management between the dental and clinical disciplines 
should be optimally and formally integrated. This aspect involves the promotion of 
clinical guidelines suitable for dental practitioners’ use, and proper training for the 
next generation of dentists.
Additionally, medical dental practitioners contribution in OSA management 
could be found in the clinically justified concern of phenotyping OSA patients, 
so that each patient is recommended the best (simple or combined) therapeutic 
variant, adjusted to the individual etiopathogenic context and to the severity of the 
disease.
On the other hand, properly designed both clinical and dental research studies 
could contribute to better specification of the various “subsets” of patients, which 
could thus benefit more from the application of a proper therapeutic variant. In this 
context, dentistry could become more useful and more effective in the management 
of OSA patients and cases of “over-treatment” or cases of malpractice could thus be 
avoided.
The role of dentistry and the involvement of dental sleep medicine specialists 
in prevention, detection, treatment of mild or moderate forms of OSA, and in 
long term management of OSA is acknowledged. Moreover, multidisciplinary and 
interdisciplinary medical path allow a holistic approach of the patient, thus provid-
ing best therapeutic results.
Promising results were achieved in the field of pharmacotherapy of OSA - as 
stand alone or in combination with other therapies. Nevertheless, more scientific 
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research and consistent clinical trials are needed in order to offer great perspectives 
for this fascinating medical domain.
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